Martin Shkreli, AKA prisoner #87850-053, has a new view to contemplate while the pharma bro serves his 7-year sentence for fraud. And he’s a lot closer to home.

On April 9, just a few weeks after Shkreli was back in the headlines with a Wall Street Journal exposé outlining his use of a contraband phone to stay in touch with the outside world and run his biotech company from Fort Dix, prison officials moved Shkreli to the Metropolitan Detention Center in Brooklyn.

Shkreli’s attorney, Benjamin Brafman, told CNBC that his client is cooling his heels in Brooklyn while waiting for a move to federal prison in Allenwood, Pennsylvania.

Prison media contacts confirmed the move to Brooklyn, but they are staying tight-lipped about the reasons for the transfer. They earlier declined comment when asked if Shkreli was being punished for breaking the rules.

Shkreli was reportedly put into solitary confinement after embarrassed prison officials had to contend with Shkreli’s alleged violation of prison rules regarding mobile phones circulating among the inmates.

Shkreli has shown his contempt for the rules on numerous occasions, frequently bashing lawmakers, reporters (“you are such a moron”) and government officials alike — anyone who criticized his move to jack up the price of an old drug by 5000%-plus. Now that he’s behind bars for a stretch, though, it’s easier to punish him for his infractions.

Shkreli established a blog not long after taking up residence at Fort Dix. But that came to a screeching halt on March 7 with his last post: “Who talked to the Jake….”

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.
Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.
Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.